Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib in HeFH or ASCVD Patients on Maximally Tolerated Lipid-Lowering Therapy
CTR20221231Phase 3Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- May 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of obicetrapib in familial hypercholesterolemia (FH), atherosclerotic disease, hypercholesterolemia, sponsored by NewAmsterdam Pharma. Started May 2022; status: completed.
02
Drugs
obicetrapib
03
Conditions
familial hypercholesterolemia (FH)atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on CTR20221231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221231.